#Gilead Sciences

The HepConnect initiative aims to expand testing, harm reduction and health care infrastructure.

The three-drug regimen beat the virus in nearly all those who had not been cured of hep C by previous treatment.

A look at the supply chain that results in very high costs for HIV and hepatitis C medications.

The subscription-based model is the first of its kind.

The placebo-controlled trial Phase III trial of selonsertib had sought to improve fibrosis while not worsening NASH.

What’s more, such treatment is linked to remission of non–Hodgkin lymphoma.

A recent study of people in British Columbia found, however, that people who inject drugs had lower cure rates.

A review of the major findings presented at the Annual Meeting of the American Association for the Study of Liver Diseases in San Francisco

In a recent trial, Gilead’s regimen was highly successful in a group that included those with and without HIV coinfection.